Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

GPCR Desensitization

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Allergen Immunotherapy for the Treatment of Eosinophilic Esophagitis. An EAACI Task Force Systematic Review.

Clinical and translational allergy·2026

Same author

Availability and Costs of Allergic Rhinitis Treatments Across the World: A Survey of ARIA Experts.

Allergy·2026

Same author

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments.

Allergy·2026

Same author

A Systematic Review and Meta-Analysis on the Induction of Confirmed Eosinophilic Esophagitis as a Side Effect of Allergen Immunotherapy: An EAACI Task Force Report.

Allergy·2025

Same author

Allergic Sensitization Worsens Respiratory Health in Children With Asthma During Dust and Pollen Periods.

Pediatric pulmonology·2025

Same author

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments.

Allergy·2025

Search research articles

Related Experiment Video

Updated: Sep 11, 2025

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

Nocebo Effect During Letrozole Desensitization: A Case Report.

Asimina Koulouridi¹, Panayiota Nikiphorou², Panayiota Gelastou¹

¹Department of Oncology, German Oncology Center, Limassol, CYP.

|August 13, 2025

Summary

A breast cancer patient experienced nocebo reactions during letrozole desensitization, not true drug allergy. Successful completion of the protocol allowed continued essential aromatase inhibitor therapy.

Keywords:

aromatase inhibitor therapy breast cancer management drug allergy documentation drug desensitization drug provocation test drug-related side effects and adverse reactions facticious disorder healthcare ethics letrozole

More Related Videos

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Experiment Videos

Last Updated: Sep 11, 2025

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Area of Science:

Oncology
Pharmacology
Immunology

Background:

Breast cancer treatment often requires adjuvant endocrine therapy, such as aromatase inhibitors.
Patients with a history of multiple drug hypersensitivity reactions may face challenges with treatment adherence.
Aromatase inhibitors are crucial for managing hormone-receptor-positive breast cancer.

Observation:

A 46-year-old woman with breast cancer and multiple drug hypersensitivities developed allergy-like symptoms to three different endocrine therapies.
She underwent a three-day desensitization protocol for letrozole, an essential aromatase inhibitor.
During the protocol, pruritic erythema occurred after placebo administration, suggesting a nocebo response.

Findings:

The letrozole desensitization protocol was successfully completed with only mild, manageable side effects like oropharyngeal pruritus and headache.
The patient was diagnosed with a nocebo reaction, not a true hypersensitivity to letrozole.
She continued daily letrozole treatment without further hypersensitivity complications.

Implications:

This case highlights the importance of differentiating nocebo reactions from true drug hypersensitivity in clinical practice.
Successful desensitization protocols can enable patients with a history of hypersensitivity to receive essential medications.
Recognizing and addressing nocebo effects can improve patient adherence and treatment outcomes in breast cancer care.